GERON CORP Payments to Acquire Available-for-sale Securities
GERON CORP (GERN) reported Payments to Acquire Available-for-sale Securities of $107.07 million for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-07-31.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2018-07-31
- GERON CORP payments to acquire available-for-sale securities for the quarter ending 2018-06-30 was $87.30M, a 171.50% increase year-over-year.
- GERON CORP payments to acquire available-for-sale securities for the quarter ending 2018-03-31 was $19.77M, a 30.10% decline year-over-year.
- GERON CORP payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $18.75M, a 20.41% decline year-over-year.
- GERON CORP payments to acquire available-for-sale securities for the quarter ending 2017-09-30 was $20.82M, a 34.08% decline year-over-year.
- GERON CORP payments to acquire available-for-sale securities for fiscal 2017 was $100.01M, a 22.63% decline from fiscal 2016.
- GERON CORP payments to acquire available-for-sale securities for fiscal 2016 was $129.25M, a 37.40% decline from fiscal 2015.
- GERON CORP payments to acquire available-for-sale securities for fiscal 2015 was $206.46M, a 8.51% increase from fiscal 2014.
- GERON CORP payments to acquire available-for-sale securities for fiscal 2014 was $190.26M, a 113.83% increase from fiscal 2013.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2018-06-30 | $87.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-31 | $107.07M 10-Q · filed 2018-07-31 | $125.81M derived: sum of 3 quarters · filed 2018-07-31 | $146.64M derived: sum of 4 quarters · filed 2018-07-31 |
| 2018-03-31 | $19.77M 10-Q · filed 2018-05-10 | $38.51M derived: sum of 2 quarters · filed 2018-05-10 | $59.34M derived: sum of 3 quarters · filed 2018-05-10 | $91.49M derived: sum of 4 quarters · filed 2018-07-31 |
| 2017-12-31 | $18.75M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $39.57M derived: sum of 2 quarters · filed 2018-03-16 | $71.72M derived: sum of 3 quarters · filed 2018-07-31 | $100.01M 10-K · filed 2018-03-16 |
| 2017-09-30 | $20.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $52.98M derived: sum of 2 quarters · filed 2018-07-31 | $81.26M 10-Q · filed 2017-11-01 | $104.81M derived: sum of 4 quarters · filed 2018-07-31 |
| 2017-06-30 | $32.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-31 | $60.44M 10-Q · filed 2018-07-31 | $83.99M derived: sum of 3 quarters · filed 2018-07-31 | $115.58M derived: sum of 4 quarters · filed 2018-07-31 |
| 2017-03-31 | $28.28M 10-Q · filed 2018-05-10 | $51.83M derived: sum of 2 quarters · filed 2018-05-10 | $83.42M derived: sum of 3 quarters · filed 2018-05-10 | $110.78M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $23.55M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $55.14M derived: sum of 2 quarters · filed 2018-03-16 | $82.50M derived: sum of 3 quarters · filed 2018-03-16 | $129.25M 10-K · filed 2018-03-16 |
| 2016-09-30 | $31.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $58.95M derived: sum of 2 quarters · filed 2017-11-01 | $105.70M 10-Q · filed 2017-11-01 | $159.08M derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-06-30 | $27.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $74.11M 10-Q · filed 2017-08-09 | $127.50M derived: sum of 3 quarters · filed 2018-03-16 | $171.48M derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-03-31 | $46.75M 10-Q · filed 2017-05-09 | $100.14M derived: sum of 2 quarters · filed 2018-03-16 | $144.12M derived: sum of 3 quarters · filed 2018-03-16 | $174.34M derived: sum of 4 quarters · filed 2018-03-16 |
| 2015-12-31 | $53.39M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $97.37M derived: sum of 2 quarters · filed 2018-03-16 | $127.59M derived: sum of 3 quarters · filed 2018-03-16 | $206.46M 10-K · filed 2018-03-16 |
| 2015-09-30 | $43.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $74.20M derived: sum of 2 quarters · filed 2016-11-03 | $153.07M 10-Q · filed 2016-11-03 | $184.16M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $30.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $109.09M 10-Q · filed 2016-08-03 | $140.18M derived: sum of 3 quarters · filed 2017-03-01 | $171.15M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $78.87M 10-Q · filed 2016-05-05 | $109.96M derived: sum of 2 quarters · filed 2017-03-01 | $140.93M derived: sum of 3 quarters · filed 2017-03-01 | $161.99M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $31.09M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $62.06M derived: sum of 2 quarters · filed 2017-03-01 | $83.12M derived: sum of 3 quarters · filed 2017-03-01 | $190.26M 10-K · filed 2017-03-01 |
| 2014-09-30 | $30.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $52.03M derived: sum of 2 quarters · filed 2015-11-05 | $159.17M 10-Q · filed 2015-11-05 | $190.70M derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-06-30 | $21.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $128.20M 10-Q · filed 2015-08-05 | $159.73M derived: sum of 3 quarters · filed 2016-03-10 | $177.07M derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-03-31 | $107.14M 10-Q · filed 2015-05-07 | $138.68M derived: sum of 2 quarters · filed 2016-03-10 | $156.01M derived: sum of 3 quarters · filed 2016-03-10 | $178.11M derived: sum of 4 quarters · filed 2016-03-10 |
| 2013-12-31 | $31.53M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $48.87M derived: sum of 2 quarters · filed 2016-03-10 | $70.97M derived: sum of 3 quarters · filed 2016-03-10 | $88.98M 10-K · filed 2016-03-10 |
| 2013-09-30 | $17.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $39.44M derived: sum of 2 quarters · filed 2014-11-05 | $57.45M 10-Q · filed 2014-11-05 | $81.91M derived: sum of 4 quarters · filed 2015-03-11 |
| 2013-06-30 | $22.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $40.11M 10-Q · filed 2014-08-11 | $64.57M derived: sum of 3 quarters · filed 2015-03-11 | $84.09M derived: sum of 4 quarters · filed 2015-03-11 |
| 2013-03-31 | $18.01M 10-Q · filed 2014-05-01 | $42.47M derived: sum of 2 quarters · filed 2015-03-11 | $61.99M derived: sum of 3 quarters · filed 2015-03-11 | $79.48M derived: sum of 4 quarters · filed 2015-03-11 |
| 2012-12-31 | $24.46M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-11 | $43.98M derived: sum of 2 quarters · filed 2015-03-11 | $61.47M derived: sum of 3 quarters · filed 2015-03-11 | $79.37M 10-K · filed 2015-03-11 |
| 2012-09-30 | $19.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $37.01M derived: sum of 2 quarters · filed 2013-11-07 | $54.91M 10-Q · filed 2013-11-07 | $95.20M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-06-30 | $17.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $35.39M 10-Q · filed 2013-08-08 | $75.69M derived: sum of 3 quarters · filed 2014-03-17 | $109.51M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-03-31 | $17.89M 10-Q · filed 2013-05-03 | $58.19M derived: sum of 2 quarters · filed 2014-03-17 | $92.02M derived: sum of 3 quarters · filed 2014-03-17 | $111.39M derived: sum of 4 quarters · filed 2014-03-17 |
| 2011-12-31 | $40.30M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $74.13M derived: sum of 2 quarters · filed 2014-03-17 | $93.50M derived: sum of 3 quarters · filed 2014-03-17 | $144.89M 10-K · filed 2014-03-17 |
| 2011-09-30 | $33.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02 | $53.20M derived: sum of 2 quarters · filed 2012-11-02 | $104.59M 10-Q · filed 2012-11-02 | $192.15M derived: sum of 4 quarters · filed 2013-03-15 |
| 2011-06-30 | $19.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $70.77M 10-Q · filed 2012-08-03 | $158.32M derived: sum of 3 quarters · filed 2013-03-15 | $195.35M derived: sum of 4 quarters · filed 2013-03-15 |
| 2011-03-31 | $51.40M 10-Q · filed 2012-05-07 | $138.95M derived: sum of 2 quarters · filed 2013-03-15 | $175.98M derived: sum of 3 quarters · filed 2013-03-15 | |
| 2010-12-31 | $87.56M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $124.59M derived: sum of 2 quarters · filed 2013-03-15 | $183.41M 10-K · filed 2013-03-15 | |
| 2010-09-30 | $37.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $95.86M 10-Q · filed 2011-11-03 | ||
| 2010-06-30 | $58.83M 10-Q · filed 2011-08-05 | |||
| 2009-12-31 | $200.11M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |